CareDx, Inc. CDNA
Nasdaq · XNAS · stock · Services-Medical Laboratories
Chart by TradingView
4/9
Piotroski F — financial health
-0.76
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $379.8M | -$21.4M | — | — | $303.1M |
| 2024 | $333.8M | $52.5M | — | — | $378.4M |
| 2023 | $280.3M | -$190.3M | — | — | $261.3M |
| 2022 | $321.8M | -$76.6M | — | — | $430.9M |
| 2021 | $296.4M | -$30.7M | — | — | $465.9M |
| 2020 | $192.2M | -$18.7M | — | — | $277.7M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.76 (distress)
- Working capital / assets 0.405
- Retained earnings / assets -1.78
- EBIT / assets -0.074
- Equity / liabilities 2.752
Source: SEC EDGAR filings · CIK 0001217234 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.